Inderal is prescribed for a range of cardiovascular and neurological indications and contains propranolol, a beta-blocking agent. The brand is registered in 24 countries, giving it a substantial international footprint without quite reaching the global ubiquity of the most widely distributed cardiovascular medications. For travellers and expatriates, it is the kind of drug that is often — but not always — recognisable on a pharmacy shelf abroad.
Propranolol is one of the oldest and most extensively studied molecules in the beta-blocker class. Inderal's registered uses span hypertension, angina pectoris, post-heart-attack management, certain cardiomyopathies, atrial fibrillation, migraine and headache prophylaxis, and tremor associated with parkinsonism. The structured indication list further down this page details how each use is recognised in the markets where the brand is sold.
Inderal's marketing authorisation reaches across several regions, with examples including Japan, Brazil, Italy, Egypt, India, and Ireland. Regulatory packaging, prescription pathways, and even the strengths sold over the counter for migraine indications versus cardiovascular ones can differ markedly from one country to another. A pharmacist in the destination market can confirm whether a propranolol product available locally — branded Inderal or otherwise — corresponds to what a patient was previously taking.
Other molecules in the beta-blocking agents class are sold in many of the same markets under different active ingredients and brand names, though they are not interchangeable without medical guidance. Anyone managing cardiovascular or migraine therapy across borders should treat substitution as a clinical decision rather than a counter-level one, and bring the question to a healthcare provider who knows the full picture.
